CGRP Receptor

Calcitonin gene-related peptide receptor

CGRP receptor is a heterodimer formed by calcitonin-receptor-like receptor (CRLR), a type II (family B) G-protein-coupled receptor, and receptor-activity-modifying protein 1 (RAMP1), a single-membrane-pass protein. RAMP1 is needed for CGRP binding and also cell-surface expression of CLR. CLR is an example of a family B GPCR.

CGRP is a neuropeptide abundant in the trigeminal system and widely expressed in both the peripheral and central nervous systems. CGRP has several functions including vasodilation, the perception of painful stimuli, and inflammation. CGRP exerts its biological action by interacting with its receptors. There are two types of CGRP receptors, CGRP-A and CGRP-B.

Adrenomedullin (1-50), rat

Cat. No.: HY-P1534

Adrenomedullin (1-50), rat is a 50 amino acid peptide, which induces a selective arterial vasodilation via activation of **CGRP1 receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Adrenomedullin (11-50), rat

Cat. No.: HY-P1766

Adrenomedullin (11-50), rat is the C-terminal fragment (11-50) of rat adrenomedullin. Rat adrenomedullin induces a selective arterial vasodilation via CGRP1 receptors.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adrenomedullin (16-31), human

Cat. No.: HY-P1770

Adrenomedullin (16-31), human is amino acid residues 16-31 fragment of human adrenomedullin (hADM). Adrenomedullin has appreciable affinity for the CGRP1 receptor. Adrenomedullin (16-31), human possesses pressor activity in the systemic vascular bed of the rat, but not the cat.

CRFGTCTVQKLAHQIY-NH2

Purity: 99.72%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Adrenomedullin (16-31), human TFA

Cat. No.: HY-P1770A

Adrenomedullin (16-31), human TFA is amino acid residues 16-31 fragment of human adrenomedullin (hADM). Adrenomedullin has appreciable affinity for the CGRP1 receptor. Adrenomedullin (16-31), human TFA possesses pressor activity in the systemic vascular bed of the rat, but not the cat.

CRFGTCTVQKLAHQIY-NH2 (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adrenomedullin (AM) (22-52), human

(22-52-Adrenomedullin (human))

Cat. No.: HY-P1471

Adrenomedullin (AM) (22-52), human, an NH2 terminal truncated adrenomedullin analogue, is an **adrenomedullin receptor** antagonist, and also antagonizes the calcitonin generelated peptide (**CGRP**) receptor in the hindlimb vascular bed of the cat.

TVQKLAHQIYQFTDKDKDNVAPRSKISPQGY-NH_2

Purity: 98.78%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Adrenomedullin (AM) (22-52), human TFA

(22-52-Adrenomedullin (human) (TFA))

Cat. No.: HY-P1471A

Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFA, an NH_2 terminal truncated adrenomedullin analogue, is an **adrenomedullin receptor** antagonist.

TVQKLAHQIYQFTDKDKDNVAPRSKISPQGY-NH_2 (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Calcitonin (human)

Cat. No.: HY-P2273

Calcitonin (human) is a hypocalcemic hormone. Calcitonin (CT) inhibits the action of osteoclast mediated bone resorption.

Purity: 96.06%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Calcitonin (salmon)

(Salmon calcitonin)

Cat. No.: HY-P0090

Calcitonin salmon, a calcium regulating hormone, is a dual-action **amylin** and **calcitonin receptor** agonist, could stimulate bone formation and inhibit bone resorption.

Purity: 98.52%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg

Calcitonin Gene Related Peptide (CGRP) (83-119), rat

Cat. No.: HY-P1462

Calcitonin Gene Related Peptide (CGRP) (83-119), rat is a 37 amino acid calcitonin family of neuropeptide, acts through calcitonin receptor-like receptor (**CRLR**).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Calcitonin Gene Related Peptide (CGRP) (83-119), rat TFA

Cat. No.: HY-P1462A

Calcitonin Gene Related Peptide (CGRP) (83-119), rat (TFA) is a 37 amino acid calcitonin family of neuropeptide, acts through calcitonin receptor-like receptor (**CRLR**).

Purity: 98.10%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

CGRP antagonist 1

Cat. No.: HY-112262

CGRP antagonist 1 is a highly potent **CGRP receptor** antagonist with a K_i and IC_{50} of 35 and 57 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eptinezumab

Cat. No.: HY-P99017

Eptinezumab is a human monoclonal antibody. Eptinezumab binds to **calcitonin gene-related peptide (CGRP)** and blocks its binding to the receptor. Eptinezumab can be used for the prevention of migraine in adults.

Eptinezumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Erenumab

Cat. No.: HY-P9938

Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (**CGRP**) receptor. Erenumab can be used for the prevention of episodic migraine.

Erenumab

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Fremanezumab

(TEV-48125)

Cat. No.: HY-P99019

Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to **calcitonin gene-related peptide (CGRP)**. CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine.

Fremanezumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Galcanezumab

(LY 2951742)

Cat. No.: HY-P99021

Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the **CGRP ligand**. Galcanezumab can be used for migraine or cluster headaches research.

Galcanezumab

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

HCGRP-(8-37)

(Human α-CGRP (8-37))

Cat. No.: HY-P1014

HCGRP-(8-37) is a human calcitonin gene-related peptide (hCGRP) fragment and also an antagonist of **CGRP receptor**.

VTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH_2

Purity: 98.0%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

HTL22562

Cat. No.: HY-145353

HTL22562 is a **calcitonin gene-related peptide (CGRP)** receptor antagonist for acute treatment of migraine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kendomycin

((-)-TAN2162)

Cat. No.: HY-121300

Kendomycin ((−)-TAN 2162) is a polyketide **antibiotic** with remarkable antibacterial and cancer cells cytotoxic activities. Kendomycin tends to be bacteriostatic rather than bactericidal and inhibits the growth of the.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-3207

Cat. No.: HY-10301

MK-3207 is a potent and orally bioavailable CGRP receptor antagonist (IC_{50} = 0.12 nM; K_i = 0.024 nM); highly selective versus human AM1, AM2, CTR, and AMY3.



Purity: 99.76%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg

MK-3207 Hydrochloride

Cat. No.: HY-10302

MK-3207 (Hydrochloride) is a potent and orally bioavailable **CGRP receptor** antagonist with IC_{50} of 0.12 nM and K_i of 0.024 nM, and is highly selective versus human AM1, AM2, CTR, and AMY3.



Purity: 99.06%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg

Olcegepant

(BIBN-4096; BIBN 4096BS) Cat. No.: HY-10095

Olcegepant (BIBN-4096) is a potent and selective non-peptide antagonist of the **calcitonin gene-related peptide 1 (CGRP1) receptor** with IC_{50} of 0.03 nM and K_i of 14.4 pM for human CGRP.



Purity: 99.50%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Olcegepant hydrochloride

(BIBN-4096 hydrochloride; BIBN4096BS hydrochloride) Cat. No.: HY-10095A

Olcegepant hydrochloride (BIBN-4096 hydrochloride) is a potent and selective non-peptide antagonist of the **calcitonin gene-related peptide 1 (CGRP1) receptor** with IC_{50} of 0.03 nM and with a K_i of 14.4 pM for human CGRP.



Purity: 99.31%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PHM-27 (human)

Cat. No.: HY-P1072

PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the **human calcitonin receptor** agonist with an EC_{50} of 11 nM.

HADGVFTSDFSKLLGQLSAKKYLESLM-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rat CGRP-(8-37)

Cat. No.: HY-P0209

Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective **CGRP receptor** antagonist.

VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF-NH_2

Purity: 98.54%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg

Rimegepant

(BMS-927711) Cat. No.: HY-15498

Rimegepant (BMS-927711) is a highly potent, oral calcitonin gene-related peptide (**CGRP**) receptor antagonist with a K_i of 0.027 nM and an IC_{50} of 0.14 nM for hCGRP receptor.



Purity: 99.08%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

SUN B8155

Cat. No.: HY-103302

SUN B8155, a non-peptide agonist of **calcitonin (CT) receptor**, selectively mimics the biological actions of calcitonin. Calcitonin, a 32-amino acid peptide hormone secreted mainly from the thyroid gland, plays an important role in maintaining bone homeostasis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Telcagepant

(MK-0974) Cat. No.: HY-32709

Telcagepant (MK-0974) is an orally active **calcitonin gene-related peptide (CGRP) receptor** antagonist with K_is of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors, respectively.



Purity: 99.55%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Ubrogepant

(MK-1602) Cat. No.: HY-12366

Ubrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (**CGRP**) antagonist in development for acute treatment of migraine.



Purity: 99.69%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Vazegepant

(Zavegepant; BHV-3500) Cat. No.: HY-134992

Vazegepant is the first intranasal **CGRP receptor** antagonist for the study the acute research of migraine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vazegepant hydrochloride

(Zavegepant hydrochloride; BHV-3500 hydrochloride) Cat. No.: HY-132131

Vazegepant (BHV-3500) hydrochloride is a highly soluble **CGRP** receptor antagonist (**hCGRP** K_i= 0.023 nM). Vazegepant hydrochloride is the first intranasal gepant for migraine.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

β-CGRP, human

(Human β-CGRP; CGRP-II (Human)) **Cat. No.:** HY-P1548

β-CGRP, human (Human β-CGRP) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC_{50}s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-CGRP, human acetate

(Human β-CGRP acetate; CGRP-II (Human) (acetate)) **Cat. No.:** HY-P1548B

β-CGRP, human acetate (Human β-CGRP acetate) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC_{50}s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-CGRP, human TFA

(Human β-CGRP TFA; CGRP-II (Human) (TFA)) **Cat. No.:** HY-P1548A

β-CGRP, human TFA (Human β-CGRP TFA) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC_{50}s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.

Purity: 99.01%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg